ITC final initial determination Ruled in favor of Hugel (no violation of Section 337)
SEOUL, South Korea, June 10, 2024 /PRNewswire/ -- Hugel Inc, a global total medical aesthetics company, announced that the Administrative Law Judge (ALJ) for its U.S. International Trade Commission(ITC) investigation issued an initial determination onJune 10th (local time) finding that "there is ...
Hugel Appointed Suk-yong Cha as Executive Chairman and Chairman of the Board Accelerating Transformation into a Global Top-tier Company
- Appointed as Executive Chairman and Chairman of the Board at the General Meeting of Shareholders and Board of Directors meeting on the 30th - Chairman Cha will lead the growth of Hugel based on his aesthetics know-how and experience in pioneering global markets SEOUL, South Korea, March 31, 20...
Hugel Nominates Suk-yong Cha as Non-Executive Director
* Hugel's 22nd General shareholders' meeting to take place on March 30th * Proposed appointment of Suk-yong Cha as new non-executive director as an agenda item SEOUL, South Korea, March 9, 2023 /PRNewswire/ -- Hugel, a global total medical aesthetic company, announced onMarch 9th that it wil...
Hugel Achieved Record-High Revenue and Operating Profit
* Hugel delivered 2022 revenue of KRW281.7bn, operating profit of KRW102.5bn, up 21.5% YoY and 7.2% YoY, respectively * Botulinum toxin's sales soared by 28.9% YoY; European sales in full swing * Hugel aims to obtain marketing approval and launch products in the U.S. within this year SEOUL, ...
Hugel's 'Letybo' First in Korea to Obtain Marketing Approval from Australia
- Obtained marketing approval on the 23rd (local time) from the Therapeutic Goods Administration (TGA) ofAustralia for the indication of glabellar lines - First shipment and local launch planned for Q1 2023...Plans to cooperate with major chain clinics and key opinion leaders SEOUL, South Korea,...
Hugel resubmits BLA for its botulinum toxin, Botulax to the U.S. FDA
* Hugel received CRL from the U.S. FDA last March and completely supplemented documents and data. * It is expected to obtain the U.S. FDA's approval in the first half of 2023 and aims to become a TOP 3 botulinum toxin brand in the U.S. market. SEOUL, South Korea, Oct. 7, 2022 /PRNewswire/ -- ...
